Content about Serono

January 4, 2013
FDA approves new delivery method for MS drug

The Food and Drug Administration has approved a new means of administration for a multiple sclerosis drug, the manufacturers said.

NEW YORK — The Food and Drug Administration has approved a new means of administration for a multiple sclerosis drug, the manufacturers said.

Pfizer and EMD Serono announced the approval of Rebif Rebidose (interferon beta-1a), a single-use auto-injector for self-administering Rebif, used to treat relapsing forms of MS. EMD Serono is the U.S. division of German drug maker Merck KGaA, so-named to avoid confusion with U.S.-based Merck & Co.

October 11, 2012
Merck KGaA to donate $1.3 million per year to academic MS research

A German drug maker is pledging millions of dollars for multiple sclerosis research, the company's U.S. subsidiary said Thursday.

ROCKLAND, Mass. — A German drug maker is pledging millions of dollars for multiple sclerosis research, the company's U.S. subsidiary said Thursday.

June 6, 2012
Dr. Reddy's, Merck KGaA partner on biosimilars

A generic drug maker in India and a German pharmaceutical company will collaborate to develop biosimilars.

HYDERABAD, India — A generic drug maker in India and a German pharmaceutical company will collaborate to develop biosimilars.

Dr. Reddy's Labs and Merck KGaA subsidiary Merck Serono announced a partnership to develop biosimilar cancer treatments, most of them monoclonal antibodies, for global markets. Based in Darmstadt, Germany, Merck KGaA operates in the United States under the name EMD to distinguish itself from U.S. drug maker Merck.

May 16, 2012
Amneal adds blackberry flavoring to generic diabetes drug

Amneal Pharmaceuticals is adding blackberry flavoring to a generic diabetes drug following feedback from customers, the company said Wednesday.

BRIDGEWATER, N.J. — Amneal Pharmaceuticals is adding blackberry flavoring to a generic diabetes drug following feedback from customers, the company said Wednesday.

Amneal announced the changes to its metformin hydrochloride immediate-release tablets in the 500-mg, 850-mg and 1,000-mg strengths, designed to cover up the smell of metformin.

March 8, 2012
Prime Therapeutics, Merck KGaA subsidiary enter contractual agreement over MS drug

A pharmacy benefit manager and the U.S. subsidiary of a German drug maker have made a deal concerning a drug for multiple sclerosis.

ST. PAUL, Minn. — A pharmacy benefit manager and the U.S. subsidiary of a German drug maker have made a deal concerning a drug for multiple sclerosis.

December 21, 2011
Genzyme reports lackluster results in MS drug trial

An orally administered drug made by Genzyme for treating multiple sclerosis did not appear superior to a biotech drug already on the market, according to results of a late-stage clinical trial.

CAMBRIDGE, Mass. — An orally administered drug made by Genzyme for treating multiple sclerosis did not appear superior to a biotech drug already on the market, according to results of a late-stage clinical trial.

Genzyme, owned by French drug maker Sanofi, compared the once-daily drug teriflunomide with Rebif (interferon beta-1a), made by Pfizer and Merck KGaA, in patients with relapsing MS in the 324-patient "TENERE" trial. Merck KGaA, based in Germany, operates under the name EMD Serono in the United States to avoid confusion with U.S.-based Merck & Co.

October 6, 2011
Merck KGaA, Ono sign agreement for oral MS, cancer drugs

German drug maker Merck KGaA will collaborate with Japanese drug maker Ono Pharmaceutical to develop oral therapies for cancer and multiple sclerosis, Merck KGaA said.

DARMSTADT, Germany — German drug maker Merck KGaA will collaborate with Japanese drug maker Ono Pharmaceutical to develop oral therapies for cancer and multiple sclerosis, Merck KGaA said.

July 7, 2011
Merck Serono names new COO

Merck KGaA division Merck Serono has appointed Belen Garijo as COO and Annalisa Jenkins as global head of drug development and medical, effective Sept. 5.

DARMSTADT, Germany — Merck KGaA division Merck Serono has appointed Belen Garijo as COO and Annalisa Jenkins as global head of drug development and medical, effective Sept. 5.

The company, which operates under the name "EMD" in the United States and is a separate company from U.S.-based Merck, said Garijo and Jenkins will be based in Geneva and will report to president Stefan Oschmann.

Garijo previously worked for Sanofi, where he was SVP global operations for the European region, while Jenkins was SVP global medical for Bristol-Myers Squibb.

March 3, 2011
Merck receives CRL for MS treatment

The Food and Drug Administration declined to approve a Merck KGaA drug designed to treat relapsing-remitting multiple sclerosis.

DARMSTADT, Germany — The Food and Drug Administration declined to approve a Merck KGaA drug designed to treat relapsing-remitting multiple sclerosis.

November 29, 2010
FDA review of MS drug extended, EMD Serono says

The Food and Drug Administration has extended its review period for a multiple sclerosis drug made by EMD Serono, the drug maker said Friday.

ROCKLAND, Mass. — The Food and Drug Administration has extended its review period for a multiple sclerosis drug made by EMD Serono, the drug maker said Friday.

EMD Serono — the U.S. subsidiary of German drug maker Merck KGaA, which uses the name to avoid confusion with U.S.-based Merck — said the FDA had extended the review time for cladribine tablets to Feb. 28. The drug is a disease-modifying drug for relapsing MS.

June 16, 2010
Clinical trial for Merck KGaA's cancer vaccine continues

A division of German drug maker Merck KGaA has resumed its clinical trial of a...